Eph signal inhibition potentiates the growth-inhibitory effects of PLK1 inhibition toward cancer cells.

Yuki, Ryuzaburo; Kuwajima, Hiroki; Ota, Ryoko; Ikeda, Yuki; Saito, Youhei; Nakayama, Yuji

Yuki, Ryuzaburo; Kuwajima, Hiroki; Ota, Ryoko; Ikeda, Yuki; Saito, Youhei; Nakayama, Yuji.

Afiliación

Yuki R; Laboratory of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan. Electronic address: yuki2019@mb.kyoto-phu.ac.jp.
Kuwajima H; Laboratory of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.
Ota R; Laboratory of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.
Ikeda Y; Laboratory of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.
Saito Y; Laboratory of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.
Nakayama Y; Laboratory of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.

Eur J Pharmacol ; 963: 176229, 2024 Jan 15.

Article en En | MEDLINE | ID: mdl-38072041

Asunto(s)

Eritropoyetina; Neoplasias; Humanos; Ciclo Celular; Proteínas de Ciclo Celular; Línea Celular Tumoral; Eritropoyetina/antagonistas & inhibidores; Mitosis; Neoplasias/tratamiento farmacológico; Proteínas Serina-Treonina Quinasas; Quinasas Tipo Polo/antagonistas & inhibidores

Palabras clave

Cancer; Centrosome separation; Eph receptor; MAPK; PLK1; Spindle assembly checkpoint

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Eritropoyetina / Neoplasias Límite: Humans Idioma: En Revista: Eur J Pharmacol Año: 2024 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google